This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
PDCO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Cardinal Health (CAH) Launches Surgical Gown for Safe Surgery
by Zacks Equity Research
Cardinal Health's (CAH) SmartGown EDGE Breathable Surgical Gown will enable clinical teams to focus on delivering safe patient care by reducing instrument handoffs and contamination.
Reasons to Add Patterson Companies (PDCO) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.
How Much Upside is Left in Merit Medical (MMSI)? Wall Street Analysts Think 25.31%
by Zacks Equity Research
The mean of analysts' price targets for Merit Medical (MMSI) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PDCO vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Ensign Group (ENSG) Q3 Earnings Beat on Occupancy, Stock Up 2.4%
by Zacks Equity Research
Ensign Group's (ENSG) third-quarter results benefit on solid segmental contribution and occupancy strength. Management currently expects adjusted EPS to be within $4.73-$4.79 for 2023.
Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.
Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merit Medical (MMSI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 15.38% and 2.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.
Merit Medical's (MMSI) New Launch to Expand Its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.
HSIC vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services
by Zacks Equity Research
Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
PDCO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study
by Zacks Equity Research
Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.
Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.
Merit Medical (MMSI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 8% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?